<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:08:23 -0700</creation_date>
  <update_date>2013-01-15 19:08:23 -0700</update_date>
  <accession>HMDBP02823</accession>
  <secondary_accessions>
    <accession>8329</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>H1R</synonym>
    <synonym>HH1R</synonym>
  </synonyms>
  <gene_name>HRH1</gene_name>
  <general_function>Involved in G-protein coupled receptor protein signaling pathway</general_function>
  <specific_function>In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB05032</accession>
      <name>Cetirizine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01927</accession>
      <name>Diphenhydramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05000</accession>
      <name>Loratadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01941</accession>
      <name>Brompheniramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05030</accession>
      <name>Fexofenadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05012</accession>
      <name>Olanzapine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01944</accession>
      <name>Chlorpheniramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05021</accession>
      <name>Quetiapine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01936</accession>
      <name>Doxylamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05020</accession>
      <name>Risperidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00870</accession>
      <name>Histamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14390</accession>
      <name>Benzatropine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14391</accession>
      <name>Ziprasidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14428</accession>
      <name>Clemastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14486</accession>
      <name>Terfenadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14498</accession>
      <name>Buclizine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14514</accession>
      <name>Mirtazapine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14549</accession>
      <name>Dexbrompheniramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13938</accession>
      <name>Promazine 5-sulfoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14571</accession>
      <name>Triprolidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14578</accession>
      <name>Cyproheptadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14620</accession>
      <name>Chlorpromazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14680</accession>
      <name>Nortriptyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14697</accession>
      <name>Hydroxyzine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14708</accession>
      <name>Cinnarizine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14775</accession>
      <name>Astemizole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14794</accession>
      <name>Trazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14805</accession>
      <name>Histamine Phosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14857</accession>
      <name>Azatadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14864</accession>
      <name>Trimipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14875</accession>
      <name>Meclizine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14886</accession>
      <name>Carbinoxamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14889</accession>
      <name>Epinastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14905</accession>
      <name>Benzquinamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14906</accession>
      <name>Olopatadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14915</accession>
      <name>Propiomazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14930</accession>
      <name>Tripelennamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14935</accession>
      <name>Tolazoline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15023</accession>
      <name>Pemirolast</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15038</accession>
      <name>Methdilazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15056</accession>
      <name>Ketotifen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15069</accession>
      <name>Maprotiline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15102</accession>
      <name>Desloratadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15120</accession>
      <name>Dimenhydrinate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15202</accession>
      <name>Promethazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15204</accession>
      <name>Mequitazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15216</accession>
      <name>Emedastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15238</accession>
      <name>Levocabastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15273</accession>
      <name>Doxepin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15277</accession>
      <name>Diphenylpyraline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15282</accession>
      <name>Desipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15304</accession>
      <name>Orphenadrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15307</accession>
      <name>Cyclizine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15367</accession>
      <name>Bromodiphenhydramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05042</accession>
      <name>Aripiprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15369</accession>
      <name>Chlorprothixene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15376</accession>
      <name>Trimeprazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15396</accession>
      <name>Paliperidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15474</accession>
      <name>Methotrimeprazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15553</accession>
      <name>Aceprometazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15556</accession>
      <name>Phenindamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15557</accession>
      <name>Pheniramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15585</accession>
      <name>Chlophedianol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15589</accession>
      <name>Flunarizine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15600</accession>
      <name>Bepotastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15620</accession>
      <name>Mianserin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15639</accession>
      <name>Mepyramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15644</accession>
      <name>Betahistine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15670</accession>
      <name>Alcaftadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15689</accession>
      <name>Antazoline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15690</accession>
      <name>Chloropyramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15691</accession>
      <name>Dimethindene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15692</accession>
      <name>Isothipendyl</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled amine receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>histamine receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:3</chromosome_location>
    <locus>3p25</locus>
    <gene_sequence>&gt;1464 bp
ATGAGCCTCCCCAATTCCTCCTGCCTCTTAGAAGACAAGATGTGTGAGGGCAACAAGACC
ACTATGGCCAGCCCCCAGCTGATGCCCCTGGTGGTGGTCCTGAGCACTATCTGCTTGGTC
ACAGTAGGGCTCAACCTGCTGGTGCTGTATGCCGTACGGAGTGAGCGGAAGCTCCACACT
GTGGGGAACCTGTACATCGTCAGCCTCTCGGTGGCGGACTTGATCGTGGGTGCCGTCGTC
ATGCCTATGAACATCCTCTACCTGCTCATGTCCAAGTGGTCACTGGGCCGTCCTCTCTGC
CTCTTTTGGCTTTCCATGGACTATGTGGCCAGCACAGCGTCCATTTTCAGTGTCTTCATC
CTGTGCATTGATCGCTACCGCTCTGTCCAGCAGCCCCTCAGGTACCTTAAGTATCGTACC
AAGACCCGAGCCTCGGCCACCATTCTGGGGGCCTGGTTTCTCTCTTTTCTGTGGGTTATT
CCCATTCTAGGCTGGAATCACTTCATGCAGCAGACCTCGGTGCGCCGAGAGGACAAGTGT
GAGACAGACTTCTATGATGTCACCTGGTTCAAGGTCATGACTGCCATCATCAACTTCTAC
CTGCCCACCTTGCTCATGCTCTGGTTCTATGCCAAGATCTACAAGGCCGTACGACAACAC
TGCCAGCACCGGGAGCTCATCAATAGGTCCCTCCCTTCCTTCTCAGAAATTAAGCTGAGG
CCAGAGAACCCCAAGGGGGATGCCAAGAAACCAGGGAAGGAGTCTCCCTGGGAGGTTCTG
AAAAGGAAGCCAAAAGATGCTGGTGGTGGATCTGTCTTGAAGTCACCATCCCAAACCCCC
AAGGAGATGAAATCCCCAGTTGTCTTCAGCCAAGAGGATGATAGAGAAGTAGACAAACTC
TACTGCTTTCCACTTGATATTGTGCACATGCAGGCTGCGGCAGAGGGGAGTAGCAGGGAC
TATGTAGCCGTCAACCGGAGCCATGGCCAGCTCAAGACAGATGAGCAGGGCCTGAACACA
CATGGGGCCAGCGAGATATCAGAGGATCAGATGTTAGGTGATAGCCAATCCTTCTCTCGA
ACGGACTCAGATACCACCACAGAGACAGCACCAGGCAAAGGCAAATTGAGGAGTGGGTCT
AACACAGGCCTGGATTACATCAAGTTTACTTGGAAGAGGCTCCGCTCGCATTCAAGACAG
TATGTATCTGGGTTGCACATGAACCGCGAAAGGAAGGCCGCCAAACAGTTGGGTTTTATC
ATGGCAGCCTTCATCCTCTGCTGGATCCCTTATTTCATCTTCTTCATGGTCATTGCCTTC
TGCAAGAACTGTTGCAATGAACATTTGCACATGTTCACCATCTGGCTGGGCTACATCAAC
TCCACACTGAACCCCCTCATCTACCCCTTGTGCAATGAGAACTTCAAGAAGACATTCAAG
AGAATTCTGCATATTCGCTCCTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>487</residue_number>
    <molecular_weight>55783.6</molecular_weight>
    <theoretical_pi>9.58</theoretical_pi>
    <pfams>
      <pfam>
        <name>7tm_1</name>
        <pfam_id>PF00001</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>30-49</region>
      <region>64-83</region>
      <region>102-123</region>
      <region>146-165</region>
      <region>190-210</region>
      <region>419-438</region>
      <region>451-470</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Histamine H1 receptor
MSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNLLVLYAVRSERKLHT
VGNLYIVSLSVADLIVGAVVMPMNILYLLMSKWSLGRPLCLFWLSMDYVASTASIFSVFI
LCIDRYRSVQQPLRYLKYRTKTRASATILGAWFLSFLWVIPILGWNHFMQQTSVRREDKC
ETDFYDVTWFKVMTAIINFYLPTLLMLWFYAKIYKAVRQHCQHRELINRSLPSFSEIKLR
PENPKGDAKKPGKESPWEVLKRKPKDAGGGSVLKSPSQTPKEMKSPVVFSQEDDREVDKL
YCFPLDIVHMQAAAEGSSRDYVAVNRSHGQLKTDEQGLNTHGASEISEDQMLGDSQSFSR
TDSDTTTETAPGKGKLRSGSNTGLDYIKFTWKRLRSHSRQYVSGLHMNRERKAAKQLGFI
MAAFILCWIPYFIFFMVIAFCKNCCNEHLHMFTIWLGYINSTLNPLIYPLCNENFKKTFK
RILHIRS</protein_sequence>
  </protein_properties>
  <genbank_protein_id>7592950</genbank_protein_id>
  <uniprot_id>P35367</uniprot_id>
  <uniprot_name>HRH1_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AB041380</genbank_gene_id>
  <genecard_id>HRH1</genecard_id>
  <geneatlas_id>HRH1</geneatlas_id>
  <hgnc_id>HGNC:5182</hgnc_id>
  <general_references>
    <reference>
      <reference_text>De Backer MD, Gommeren W, Moereels H, Nobels G, Van Gompel P, Leysen JE, Luyten WH: Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor. Biochem Biophys Res Commun. 1993 Dec 30;197(3):1601-8.</reference_text>
      <pubmed_id>8280179</pubmed_id>
    </reference>
    <reference>
      <reference_text>Fukui H, Fujimoto K, Mizuguchi H, Sakamoto K, Horio Y, Takai S, Yamada K, Ito S: Molecular cloning of the human histamine H1 receptor gene.  Biochem Biophys Res Commun. 1994 Jun 15;201(2):894-901.</reference_text>
      <pubmed_id>8003029</pubmed_id>
    </reference>
    <reference>
      <reference_text>Moguilevsky N, Varsalona F, Noyer M, Gillard M, Guillaume JP, Garcia L, Szpirer C, Szpirer J, Bollen A: Stable expression of human H1-histamine-receptor cDNA in Chinese hamster ovary cells. Pharmacological characterisation of the protein, tissue distribution of messenger RNA and chromosomal localisation of the gene. Eur J Biochem. 1994 Sep 1;224(2):489-95.</reference_text>
      <pubmed_id>7925364</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kitano T, Liu YH, Ueda S, Saitou N: Human-specific amino acid changes found in 103 protein-coding genes.  Mol Biol Evol. 2004 May;21(5):936-44. Epub 2004 Mar 10.</reference_text>
      <pubmed_id>15014171</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R, Greff Z, Keri G, Stemmann O, Mann M: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell. 2008 Aug 8;31(3):438-48.</reference_text>
      <pubmed_id>18691976</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP: A quantitative atlas of mitotic phosphorylation.  Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7. Epub 2008 Jul 31.</reference_text>
      <pubmed_id>18669648</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers.  Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.</reference_text>
      <pubmed_id>16959974</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Benzatropine</name>
        <accession>HMDB14390</accession>
      </metabolite>
      <reference>
        <reference_text>Kulkarni SS, Kopajtic TA, Katz JL, Newman AH: Comparative structure-activity relationships of benztropine analogues at the dopamine transporter and histamine H(1) receptors. Bioorg Med Chem. 2006 Jun 1;14(11):3625-34. Epub 2006 Feb 3.</reference_text>
        <pubmed_id>16460947</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</reference_text>
        <pubmed_id>11132243</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Arnt J: Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol. 1995 Sep 5;283(1-3):55-62.</reference_text>
        <pubmed_id>7498321</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clemastine</name>
        <accession>HMDB14428</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clemastine</name>
        <accession>HMDB14428</accession>
      </metabolite>
      <reference>
        <reference_text>Taniguchi K, Urakami M, Takanaka K: [Effects of antiallergic agents on polymorphonuclear leukocytes. The inhibition of arachidonic acid release and superoxide production]. Nihon Yakurigaku Zasshi. 1987 Aug;90(2):97-103.</reference_text>
        <pubmed_id>2890562</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clemastine</name>
        <accession>HMDB14428</accession>
      </metabolite>
      <reference>
        <reference_text>Hallberg T, Dohlsten M, Baldetorp B: Demonstration of histamine receptors on human platelets by flow cytometry.  Scand J Haematol. 1984 Feb;32(2):113-8.</reference_text>
        <pubmed_id>6701456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clemastine</name>
        <accession>HMDB14428</accession>
      </metabolite>
      <reference>
        <reference_text>Dorsch W, Hintschich C, Neuhauser J, Weber J: Sequential histamine inhalations cause increased bronchial histamine reactivity in guinea pigs: role of platelets, thromboxanes and prostacyclin. Naunyn Schmiedebergs Arch Pharmacol. 1984 Sep;327(2):148-55.</reference_text>
        <pubmed_id>6387510</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clemastine</name>
        <accession>HMDB14428</accession>
      </metabolite>
      <reference>
        <reference_text>Taniguchi K, Masuda Y, Takanaka K: Inhibitory effects of histamine H1 receptor blocking drugs on metabolic activations of neutrophils. J Pharmacobiodyn. 1991 Feb;14(2):87-93.</reference_text>
        <pubmed_id>1678430</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clemastine</name>
        <accession>HMDB14428</accession>
      </metabolite>
      <reference>
        <reference_text>Oishi R, Shishido S, Yamori M, Saeki K: Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4.</reference_text>
        <pubmed_id>7513381</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clemastine</name>
        <accession>HMDB14428</accession>
      </metabolite>
      <reference>
        <reference_text>Thomas RH, Browne PD, Kirby JD: The influence of ranitidine, alone and in combination with clemastine, on histamine-mediated cutaneous weal and flare reactions in human skin. Br J Clin Pharmacol. 1985 Oct;20(4):377-82.</reference_text>
        <pubmed_id>4074605</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clemastine</name>
        <accession>HMDB14428</accession>
      </metabolite>
      <reference>
        <reference_text>Thomson NC, Kerr JW: Effect of inhaled H1 and H2 receptor antagonist in normal and asthmatic subjects.  Thorax. 1980 Jun;35(6):428-34.</reference_text>
        <pubmed_id>6449094</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clemastine</name>
        <accession>HMDB14428</accession>
      </metabolite>
      <reference>
        <reference_text>Hayashi H, Okajima M, Yamada K: Atrial T (Ta) loop in dogs with or without atrial injury.  Am Heart J. 1976 May;91(5):607-17.</reference_text>
        <pubmed_id>1266718</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clemastine</name>
        <accession>HMDB14428</accession>
      </metabolite>
      <reference>
        <reference_text>Schran HF, Petryk L, Chang CT, O'Connor R, Gelbert MB: The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. J Clin Pharmacol. 1996 Oct;36(10):911-22.</reference_text>
        <pubmed_id>8930778</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Kishimoto W, Hiroi T, Sakai K, Funae Y, Igarashi T: Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.</reference_text>
        <pubmed_id>9485522</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF 3rd, Guinosso PJ Jr, Lynch JJ Jr: Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 1995 Jan;76(1):110-9.</reference_text>
        <pubmed_id>8001268</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Wood-Baker R, Smith R, Holgate ST: A double-blind, placebo controlled study of the effect of the specific histamine H1-receptor antagonist, terfenadine, in chronic severe asthma. Br J Clin Pharmacol. 1995 Jun;39(6):671-5.</reference_text>
        <pubmed_id>7654486</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Phillips GD, Polosa R, Holgate ST: The effect of histamine-H1 receptor antagonism with terfenadine on concentration-related AMP-induced bronchoconstriction in asthma. Clin Exp Allergy. 1989 Jul;19(4):405-9.</reference_text>
        <pubmed_id>2569356</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Rafferty P, Holgate ST: Terfenadine (Seldane) is a potent and selective histamine H1 receptor antagonist in asthmatic airways. Am Rev Respir Dis. 1987 Jan;135(1):181-4.</reference_text>
        <pubmed_id>2879489</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Buclizine</name>
        <accession>HMDB14498</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Buclizine</name>
        <accession>HMDB14498</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Buclizine</name>
        <accession>HMDB14498</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mirtazapine</name>
        <accession>HMDB14514</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexbrompheniramine</name>
        <accession>HMDB14549</accession>
      </metabolite>
      <reference>
        <reference_text>McLeod RL, Mingo G, O'Reilly S, Ruck LA, Bolser DC, Hey JA: Antitussive action of antihistamines is independent of sedative and ventilation activity in the guinea pig. Pharmacology. 1998 Aug;57(2):57-64.</reference_text>
        <pubmed_id>9691225</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexbrompheniramine</name>
        <accession>HMDB14549</accession>
      </metabolite>
      <reference>
        <reference_text>Bokesoy TA, Onaran HO: Atypical Schild plots with histamine H1 receptor agonists and antagonists in the rabbit aorta. Eur J Pharmacol. 1991 May 2;197(1):49-56.</reference_text>
        <pubmed_id>1680053</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexbrompheniramine</name>
        <accession>HMDB14549</accession>
      </metabolite>
      <reference>
        <reference_text>Onaran HO, Bokesoy TA: Kinetics of antagonism at histamine-H1 receptors in isolated rabbit arteries.  Naunyn Schmiedebergs Arch Pharmacol. 1990 Apr;341(4):316-23.</reference_text>
        <pubmed_id>1970615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexbrompheniramine</name>
        <accession>HMDB14549</accession>
      </metabolite>
      <reference>
        <reference_text>Yanni JM, Stephens DJ, Parnell DW, Spellman JM: Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol. 1994 Winter;10(4):665-75.</reference_text>
        <pubmed_id>7714410</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexbrompheniramine</name>
        <accession>HMDB14549</accession>
      </metabolite>
      <reference>
        <reference_text>Sadofsky LR, Campi B, Trevisani M, Compton SJ, Morice AH: Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine. Exp Lung Res. 2008 Dec;34(10):681-93.</reference_text>
        <pubmed_id>19085565</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexbrompheniramine</name>
        <accession>HMDB14549</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.</reference_text>
        <pubmed_id>2899826</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triprolidine</name>
        <accession>HMDB14571</accession>
      </metabolite>
      <reference>
        <reference_text>Peroutka SJ, Snyder SH: Two distinct serotonin receptors: regional variations in receptor binding in mammalian brain. Brain Res. 1981 Mar 16;208(2):339-47.</reference_text>
        <pubmed_id>7214150</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triprolidine</name>
        <accession>HMDB14571</accession>
      </metabolite>
      <reference>
        <reference_text>Claro E, Arbones L, Garcia A, Picatoste F: Phosphoinositide hydrolysis mediated by histamine H1-receptors in rat brain cortex. Eur J Pharmacol. 1986 Apr 16;123(2):187-96.</reference_text>
        <pubmed_id>3011460</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triprolidine</name>
        <accession>HMDB14571</accession>
      </metabolite>
      <reference>
        <reference_text>Kuzmin AI, Zaretsky DV, Kalenikova EI, Zaretskaja MV, Medvedev OS, Chazov EI: The effect of histamine receptor antagonists on stress-induced catecholamine secretion: an adrenomedullary microdialysis study in the rat. Eur J Pharmacol. 1999 Aug 13;378(3):311-6.</reference_text>
        <pubmed_id>10493107</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triprolidine</name>
        <accession>HMDB14571</accession>
      </metabolite>
      <reference>
        <reference_text>Ziganshina LE, Ziganshin AU, Hoyle CH, Burnstock G: Acute paw oedema formation induced by ATP: re-evaluation of the mechanisms involved. Inflamm Res. 1996 Feb;45(2):96-102.</reference_text>
        <pubmed_id>8907591</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triprolidine</name>
        <accession>HMDB14571</accession>
      </metabolite>
      <reference>
        <reference_text>Hiroi T, Ohishi N, Imaoka S, Yabusaki Y, Fukui H, Funae Y: Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. J Pharmacol Exp Ther. 1995 Feb;272(2):939-44.</reference_text>
        <pubmed_id>7853212</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triprolidine</name>
        <accession>HMDB14571</accession>
      </metabolite>
      <reference>
        <reference_text>Estelle F, Simons R: H1-receptor antagonists: safety issues.  Ann Allergy Asthma Immunol. 1999 Nov;83(5):481-8.</reference_text>
        <pubmed_id>10582735</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triprolidine</name>
        <accession>HMDB14571</accession>
      </metabolite>
      <reference>
        <reference_text>Mann KV, Crowe JP, Tietze KJ: Nonsedating histamine H1-receptor antagonists.  Clin Pharm. 1989 May;8(5):331-44.</reference_text>
        <pubmed_id>2568212</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triprolidine</name>
        <accession>HMDB14571</accession>
      </metabolite>
      <reference>
        <reference_text>Simons FE: H1-receptor antagonists. Comparative tolerability and safety.  Drug Saf. 1994 May;10(5):350-80.</reference_text>
        <pubmed_id>7913608</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triprolidine</name>
        <accession>HMDB14571</accession>
      </metabolite>
      <reference>
        <reference_text>Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).  Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97.</reference_text>
        <pubmed_id>2866055</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triprolidine</name>
        <accession>HMDB14571</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyproheptadine</name>
        <accession>HMDB14578</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.</reference_text>
        <pubmed_id>2899826</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Church MK, Young KD: The characteristics of inhibition of histamine release from human lung fragments by sodium cromoglycate, salbutamol and chlorpromazine. Br J Pharmacol. 1983 Apr;78(4):671-9.</reference_text>
        <pubmed_id>6189542</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Johnson HG, Miller MD: Inhibition of histamine release and ionophore-induced calcium flux in rat mast cells by lidocaine and chlorpromazine. Agents Actions. 1979 Aug;9(3):239-43.</reference_text>
        <pubmed_id>91313</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Palmer GC, Wagner HR, Palmer SJ, Manian AA: Histamine-, norepinephrine-, and dopamine-sensitive central adenylate cyclases: effects of chlorpromazine derivatives and butaclamol. Arch Int Pharmacodyn Ther. 1978 Jun;233(2):314-25.</reference_text>
        <pubmed_id>687395</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Ruffolo RR, Patil PN: Kinetics of blockade of different receptors by chlorpromazine in rabbit stomach strips. Eur J Pharmacol. 1978 Mar 15;48(2):151-7.</reference_text>
        <pubmed_id>25190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Sadava D, Wilmington K: Tricyclic antidepressant drugs affect histamine receptors in human leukocytes.  Life Sci. 1984 Dec 17;35(25):2545-8.</reference_text>
        <pubmed_id>6096660</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzine</name>
        <accession>HMDB14697</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzine</name>
        <accession>HMDB14697</accession>
      </metabolite>
      <reference>
        <reference_text>Spahr L, Coeytaux A, Giostra E, Hadengue A, Annoni JM: Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol. 2007 Apr;102(4):744-53. Epub 2007 Jan 11.</reference_text>
        <pubmed_id>17222324</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzine</name>
        <accession>HMDB14697</accession>
      </metabolite>
      <reference>
        <reference_text>Sakaguchi T, Itoh H, Ding WG, Tsuji K, Nagaoka I, Oka Y, Ashihara T, Ito M, Yumoto Y, Zenda N, Higashi Y, Takeyama Y, Matsuura H, Horie M: Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. J Pharmacol Sci. 2008 Dec;108(4):462-71. Epub 2008 Dec 5.</reference_text>
        <pubmed_id>19057127</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzine</name>
        <accession>HMDB14697</accession>
      </metabolite>
      <reference>
        <reference_text>Chen C: Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem. 2008;15(21):2173-91.</reference_text>
        <pubmed_id>18781943</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzine</name>
        <accession>HMDB14697</accession>
      </metabolite>
      <reference>
        <reference_text>Snowman AM, Snyder SH: Cetirizine: actions on neurotransmitter receptors.  J Allergy Clin Immunol. 1990 Dec;86(6 Pt 2):1025-8.</reference_text>
        <pubmed_id>1979798</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cinnarizine</name>
        <accession>HMDB14708</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cinnarizine</name>
        <accession>HMDB14708</accession>
      </metabolite>
      <reference>
        <reference_text>Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).  Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97.</reference_text>
        <pubmed_id>2866055</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF 3rd, Guinosso PJ Jr, Lynch JJ Jr: Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 1995 Jan;76(1):110-9.</reference_text>
        <pubmed_id>8001268</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Howarth PH, Emanuel MB, Holgate ST: Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels. Br J Clin Pharmacol. 1984 Jul;18(1):1-8.</reference_text>
        <pubmed_id>6146346</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Kaliner MA, Check WA: Non-sedating antihistamines.  Allergy Proc. 1988 Nov-Dec;9(6):649-63.</reference_text>
        <pubmed_id>3147222</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Cavero I, Mestre M, Guillon JM, Heuillet E, Roach AG: Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans? Drug Saf. 1999;21 Suppl 1:19-31; discussion 81-7.</reference_text>
        <pubmed_id>10597865</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Llenas J, Cardelus I, Heredia A, de Mora F, Gristwood RW: Cardiotoxicity of histamine and the possible role of histamine in the arrhythmogenesis produced by certain antihistamines. Drug Saf. 1999;21 Suppl 1:33-8; discussion 81-7.</reference_text>
        <pubmed_id>10597866</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Richards DM, Brogden RN, Heel RC, Speight TM, Avery GS: Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy.  Drugs. 1984 Jul;28(1):38-61.</reference_text>
        <pubmed_id>6204835</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Krstenansky PM, Cluxton RJ Jr: Astemizole: a long-acting, nonsedating antihistamine.  Drug Intell Clin Pharm. 1987 Dec;21(12):947-53.</reference_text>
        <pubmed_id>2892659</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trazodone</name>
        <accession>HMDB14794</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trazodone</name>
        <accession>HMDB14794</accession>
      </metabolite>
      <reference>
        <reference_text>Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102.</reference_text>
        <pubmed_id>6086881</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trazodone</name>
        <accession>HMDB14794</accession>
      </metabolite>
      <reference>
        <reference_text>Noguchi S, Inukai T, Kuno T, Tanaka C: The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking. Physiol Behav. 1992 Jun;51(6):1123-7.</reference_text>
        <pubmed_id>1353628</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Histamine Phosphate</name>
        <accession>HMDB14805</accession>
      </metabolite>
      <reference>
        <reference_text>Miyoshi K, Das AK, Fujimoto K, Horio S, Fukui H: Recent advances in molecular pharmacology of the histamine systems: regulation of histamine H1 receptor signaling by changing its expression level. J Pharmacol Sci. 2006 May;101(1):3-6. Epub 2006 Apr 28.</reference_text>
        <pubmed_id>16648669</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Histamine Phosphate</name>
        <accession>HMDB14805</accession>
      </metabolite>
      <reference>
        <reference_text>Han SK, Mancino V, Simon MI: Phospholipase cbeta 3 mediates the scratching response activated by the histamine h1 receptor on C-fiber nociceptive neurons. Neuron. 2006 Nov 22;52(4):691-703.</reference_text>
        <pubmed_id>17114052</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Histamine Phosphate</name>
        <accession>HMDB14805</accession>
      </metabolite>
      <reference>
        <reference_text>Spahr L, Coeytaux A, Giostra E, Hadengue A, Annoni JM: Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol. 2007 Apr;102(4):744-53. Epub 2007 Jan 11.</reference_text>
        <pubmed_id>17222324</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Histamine Phosphate</name>
        <accession>HMDB14805</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki K, Morokata T, Morihira K, Sato I, Takizawa S, Kaneko M, Takahashi K, Shimizu Y: A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor.  Eur J Pharmacol. 2007 Jun 1;563(1-3):224-32. Epub 2007 Feb 8.</reference_text>
        <pubmed_id>17336292</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Histamine Phosphate</name>
        <accession>HMDB14805</accession>
      </metabolite>
      <reference>
        <reference_text>Tanimoto A, Wang KY, Murata Y, Kimura S, Nomaguchi M, Nakata S, Tsutsui M, Sasaguri Y: Histamine upregulates the expression of inducible nitric oxide synthase in human intimal smooth muscle cells via histamine H1 receptor and NF-kappaB signaling pathway. Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1556-61. Epub 2007 May 3.</reference_text>
        <pubmed_id>17478759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azatadine</name>
        <accession>HMDB14857</accession>
      </metabolite>
      <reference>
        <reference_text>Singh N, Puri SK: Causal prophylactic activity of antihistaminic agents against Plasmodium yoelii nigeriensis infection in Swiss mice. Acta Trop. 1998 Jun;69(3):255-60.</reference_text>
        <pubmed_id>9638277</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azatadine</name>
        <accession>HMDB14857</accession>
      </metabolite>
      <reference>
        <reference_text>Mann KV, Crowe JP, Tietze KJ: Nonsedating histamine H1-receptor antagonists.  Clin Pharm. 1989 May;8(5):331-44.</reference_text>
        <pubmed_id>2568212</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azatadine</name>
        <accession>HMDB14857</accession>
      </metabolite>
      <reference>
        <reference_text>Clissold SP, Sorkin EM, Goa KL: Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1989 Jan;37(1):42-57.</reference_text>
        <pubmed_id>2523301</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azatadine</name>
        <accession>HMDB14857</accession>
      </metabolite>
      <reference>
        <reference_text>Haria M, Fitton A, Peters DH: Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994 Oct;48(4):617-37.</reference_text>
        <pubmed_id>7528133</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azatadine</name>
        <accession>HMDB14857</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimipramine</name>
        <accession>HMDB14864</accession>
      </metabolite>
      <reference>
        <reference_text>Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives.  Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9.</reference_text>
        <pubmed_id>8863001</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meclizine</name>
        <accession>HMDB14875</accession>
      </metabolite>
      <reference>
        <reference_text>Oishi R, Shishido S, Yamori M, Saeki K: Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4.</reference_text>
        <pubmed_id>7513381</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meclizine</name>
        <accession>HMDB14875</accession>
      </metabolite>
      <reference>
        <reference_text>Martins MA, Pasquale CP, e Silva PM, Pires AL, Ruffie C, Rihoux JP, Cordeiro RS, Vargaftig BB: Interference of cetirizine with the late eosinophil accumulation induced by either PAF or compound 48/80. Br J Pharmacol. 1992 Jan;105(1):176-80.</reference_text>
        <pubmed_id>1350745</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meclizine</name>
        <accession>HMDB14875</accession>
      </metabolite>
      <reference>
        <reference_text>Pasquale CP, e Silva PM, Lima MC, Diaz BL, Rihoux JP, Vargaftig BB, Cordeiro RS, Martins MA: Suppression by cetirizine of pleurisy triggered by antigen in actively sensitized rats. Eur J Pharmacol. 1992 Nov 13;223(1):9-14.</reference_text>
        <pubmed_id>1362160</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meclizine</name>
        <accession>HMDB14875</accession>
      </metabolite>
      <reference>
        <reference_text>Taniguchi K, Masuda Y, Takanaka K: Inhibitory effects of histamine H1 receptor blocking drugs on metabolic activations of neutrophils. J Pharmacobiodyn. 1991 Feb;14(2):87-93.</reference_text>
        <pubmed_id>1678430</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbinoxamine</name>
        <accession>HMDB14886</accession>
      </metabolite>
      <reference>
        <reference_text>Oishi R, Shishido S, Yamori M, Saeki K: Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4.</reference_text>
        <pubmed_id>7513381</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbinoxamine</name>
        <accession>HMDB14886</accession>
      </metabolite>
      <reference>
        <reference_text>Ramadan AA, Mandil H: Spectrophotometric determination of carbinoxamine maleate in pharmaceutical formulations by ternary complex formation with Cu(II) and eosin. Anal Biochem. 2006 Jun 1;353(1):133-7. Epub 2006 Mar 9.</reference_text>
        <pubmed_id>16574052</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbinoxamine</name>
        <accession>HMDB14886</accession>
      </metabolite>
      <reference>
        <reference_text>Darby WJ: Nutrition, food needs and technologic priorities: the World Food Conference.  Nutr Rev. 1975 Aug;33(8):225-34.</reference_text>
        <pubmed_id>1143714</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbinoxamine</name>
        <accession>HMDB14886</accession>
      </metabolite>
      <reference>
        <reference_text>Yang J, Dudley GB: [1,2]-Anionic rearrangement of 2-benzyloxypyridine and related pyridyl ethers.  J Org Chem. 2009 Oct 16;74(20):7998-8000.</reference_text>
        <pubmed_id>19761204</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbinoxamine</name>
        <accession>HMDB14886</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Epinastine</name>
        <accession>HMDB14889</accession>
      </metabolite>
      <reference>
        <reference_text>Tsujii T, Yamamoto E, Ohira T, Saito N, Watanabe S: Effects of sedative and non-sedative H1 antagonists on cognitive tasks: behavioral and near-infrared spectroscopy (NIRS) examinations. Psychopharmacology (Berl). 2007 Sep;194(1):83-91. Epub 2007 May 30.</reference_text>
        <pubmed_id>17534605</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Epinastine</name>
        <accession>HMDB14889</accession>
      </metabolite>
      <reference>
        <reference_text>Walther G, Daniel H, Bechtel WD, Brandt K: New tetracyclic guanidine derivatives with H1-antihistaminic properties. Chemistry of epinastine. Arzneimittelforschung. 1990 Apr;40(4):440-6.</reference_text>
        <pubmed_id>1972625</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Epinastine</name>
        <accession>HMDB14889</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzquinamide</name>
        <accession>HMDB14905</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzquinamide</name>
        <accession>HMDB14905</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzquinamide</name>
        <accession>HMDB14905</accession>
      </metabolite>
      <reference>
        <reference_text>Maurer H, Pfleger K: Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. J Chromatogr. 1988 Aug 19;430(1):31-41.</reference_text>
        <pubmed_id>2905706</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzquinamide</name>
        <accession>HMDB14905</accession>
      </metabolite>
      <reference>
        <reference_text>Niemegeers CJ: Antiemetic specificity of dopamine antagonists.  Psychopharmacology (Berl). 1982;78(3):210-3.</reference_text>
        <pubmed_id>6130555</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Olopatadine</name>
        <accession>HMDB14906</accession>
      </metabolite>
      <reference>
        <reference_text>Tamura T, Masaki S, Ohmori K, Karasawa A: Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology. 2005 Dec;75(1):45-52. Epub 2005 Jun 7.</reference_text>
        <pubmed_id>15942272</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Olopatadine</name>
        <accession>HMDB14906</accession>
      </metabolite>
      <reference>
        <reference_text>Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97.</reference_text>
        <pubmed_id>12046981</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Olopatadine</name>
        <accession>HMDB14906</accession>
      </metabolite>
      <reference>
        <reference_text>Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400.</reference_text>
        <pubmed_id>8951675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Olopatadine</name>
        <accession>HMDB14906</accession>
      </metabolite>
      <reference>
        <reference_text>Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug.  Arzneimittelforschung. 2004;54(12):809-29.</reference_text>
        <pubmed_id>15646365</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Olopatadine</name>
        <accession>HMDB14906</accession>
      </metabolite>
      <reference>
        <reference_text>Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon Yakurigaku Zasshi. 2001 Jul;118(1):51-8.</reference_text>
        <pubmed_id>11496828</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Olopatadine</name>
        <accession>HMDB14906</accession>
      </metabolite>
      <reference>
        <reference_text>Roland PS, Ryan MW, Wall GM: Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother. 2010 Jun;11(9):1559-67.</reference_text>
        <pubmed_id>20482305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Olopatadine</name>
        <accession>HMDB14906</accession>
      </metabolite>
      <reference>
        <reference_text>Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities.  Allergy Asthma Proc. 2010 Mar-Apr;31(2):112-9.</reference_text>
        <pubmed_id>20406593</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Olopatadine</name>
        <accession>HMDB14906</accession>
      </metabolite>
      <reference>
        <reference_text>Roland PS, Marple BF, Wall GM: Olopatadine nasal spray for the treatment of allergic rhinitis.  Expert Rev Clin Immunol. 2010 Mar;6(2):197-204.</reference_text>
        <pubmed_id>20402382</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Olopatadine</name>
        <accession>HMDB14906</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propiomazine</name>
        <accession>HMDB14915</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propiomazine</name>
        <accession>HMDB14915</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propiomazine</name>
        <accession>HMDB14915</accession>
      </metabolite>
      <reference>
        <reference_text>KRAKOWSKI AJ: Propiomazine for control of insomnia in nervous disorders.  Am J Psychiatry. 1962 Nov;119:461-2.</reference_text>
        <pubmed_id>14035428</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propiomazine</name>
        <accession>HMDB14915</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tripelennamine</name>
        <accession>HMDB14930</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tripelennamine</name>
        <accession>HMDB14930</accession>
      </metabolite>
      <reference>
        <reference_text>Shimizu K, Nakajyo S, Urakawa N: [Drug sensitivity of the isolated stomach and ileal preparation from a vole].  Nihon Heikatsukin Gakkai Zasshi. 1982 May;18(2):93-103.</reference_text>
        <pubmed_id>6759742</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tripelennamine</name>
        <accession>HMDB14930</accession>
      </metabolite>
      <reference>
        <reference_text>Chiba S: Blocking effect of tripelennamine on histamine--induced positive chronotropic and inotropic responses of the dog atrium. Tohoku J Exp Med. 1976 Nov;120(3):299-300.</reference_text>
        <pubmed_id>996853</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tripelennamine</name>
        <accession>HMDB14930</accession>
      </metabolite>
      <reference>
        <reference_text>Sansone M: Antihistaminic-opioid combination: effect on locomotor activity in mice.  Pol J Pharmacol Pharm. 1988 Sep-Oct;40(5):515-23.</reference_text>
        <pubmed_id>3253717</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tripelennamine</name>
        <accession>HMDB14930</accession>
      </metabolite>
      <reference>
        <reference_text>Ohta Y, Kobayashi T, Ishiguro I: Role of endogenous serotonin and histamine in the pathogenesis of gastric mucosal lesions in unanaesthetised rats with a single treatment of compound 48/80, a mast cell degranulator. Pharmacol Res. 1999 Apr;39(4):261-7.</reference_text>
        <pubmed_id>10208755</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tripelennamine</name>
        <accession>HMDB14930</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki T, Mori T, Tsuji M, Misawa M, Onodera K: Interactions between H1-antagonists and opioids: a drug discrimination study.  Psychopharmacology (Berl). 1997 Jun;131(4):346-53.</reference_text>
        <pubmed_id>9226736</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolazoline</name>
        <accession>HMDB14935</accession>
      </metabolite>
      <reference>
        <reference_text>Roll C, Hanssler L: [Interaction of tolazoline and cimetidine in persistent fetal circulation of the newborn infant]. Monatsschr Kinderheilkd. 1993 Apr;141(4):297-9.</reference_text>
        <pubmed_id>8487790</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemirolast</name>
        <accession>HMDB15023</accession>
      </metabolite>
      <reference>
        <reference_text>Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu S, Sharif NA: Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol. 1997 Dec;79(6):541-5.</reference_text>
        <pubmed_id>9433371</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemirolast</name>
        <accession>HMDB15023</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pemirolast</name>
        <accession>HMDB15023</accession>
      </metabolite>
      <reference>
        <reference_text>Kobayashi K, Hiroi J, Kishi S, Sawase K, Hirayama Y, Chihara S, Imai T, Shigi Y, Shimomura K, Kohsaka M: Effects of quinotolast, a new orally active antiallergic drug, on experimental allergic models. Jpn J Pharmacol. 1993 Sep;63(1):73-81.</reference_text>
        <pubmed_id>7505860</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methdilazine</name>
        <accession>HMDB15038</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methdilazine</name>
        <accession>HMDB15038</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methdilazine</name>
        <accession>HMDB15038</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methdilazine</name>
        <accession>HMDB15038</accession>
      </metabolite>
      <reference>
        <reference_text>Chattopadhyay D, Mukherjee T, Pal P, Saha B, Bhadra R: Altered membrane permeability as the basis of bactericidal action of methdilazine. J Antimicrob Chemother. 1998 Jul;42(1):83-6.</reference_text>
        <pubmed_id>9700532</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methdilazine</name>
        <accession>HMDB15038</accession>
      </metabolite>
      <reference>
        <reference_text>Dasgupta A, Chaki S, Mukherjee S, Lourduraja J, Mazumdar K, Dutta NK, Dastidar SG: Experimental analyses of synergistic combinations of antibiotics with a recently recognised antibacterial agent, lacidipine. Eur J Clin Microbiol Infect Dis. 2010 Feb;29(2):239-43. Epub 2009 Dec 13.</reference_text>
        <pubmed_id>20012879</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketotifen</name>
        <accession>HMDB15056</accession>
      </metabolite>
      <reference>
        <reference_text>Mita H, Shida T: Comparison of anti-allergic activities of the histamine H1 receptor antagonists epinastine, ketotifen and oxatomide in human leukocytes. Arzneimittelforschung. 1995 Jan;45(1):36-40.</reference_text>
        <pubmed_id>7893266</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketotifen</name>
        <accession>HMDB15056</accession>
      </metabolite>
      <reference>
        <reference_text>Okabe S, Nakaji S, Tachibana M: Effect of ketotifen on acute gastric lesions and gastric secretion in rats.  Jpn J Pharmacol. 1992 Jun;59(2):251-4.</reference_text>
        <pubmed_id>1434122</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketotifen</name>
        <accession>HMDB15056</accession>
      </metabolite>
      <reference>
        <reference_text>Hashimoto T, Ohata H, Honda K: Lysophosphatidic acid (LPA) induces plasma exudation and histamine release in mice via LPA receptors. J Pharmacol Sci. 2006 Jan;100(1):82-7. Epub 2006 Jan 11.</reference_text>
        <pubmed_id>16404130</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketotifen</name>
        <accession>HMDB15056</accession>
      </metabolite>
      <reference>
        <reference_text>Ito K, Sakamoto T, Hayashi Y, Morishita M, Shibata E, Sakai K, Takeuchi Y, Torii S: Role of tachykinin and bradykinin receptors and mast cells in gaseous formaldehyde-induced airway microvascular leakage in rats. Eur J Pharmacol. 1996 Jul 4;307(3):291-8.</reference_text>
        <pubmed_id>8836617</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketotifen</name>
        <accession>HMDB15056</accession>
      </metabolite>
      <reference>
        <reference_text>Yokoyama H, Iinuma K, Yanai K, Watanabe T, Sakurai E, Onodera K: Proconvulsant effect of ketotifen, a histamine H1 antagonist, confirmed by the use of d-chlorpheniramine with monitoring electroencephalography. Methods Find Exp Clin Pharmacol. 1993 Apr;15(3):183-8.</reference_text>
        <pubmed_id>8101246</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketotifen</name>
        <accession>HMDB15056</accession>
      </metabolite>
      <reference>
        <reference_text>Werner-Klein M, Goggel R, Westhof A, Erb KJ: Development and characterisation of a novel and rapid lung eosinophil influx model in the rat. Pulm Pharmacol Ther. 2008 Aug;21(4):648-56. Epub 2008 Apr 7.</reference_text>
        <pubmed_id>18490184</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketotifen</name>
        <accession>HMDB15056</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Noguchi S, Inukai T, Kuno T, Tanaka C: The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking. Physiol Behav. 1992 Jun;51(6):1123-7.</reference_text>
        <pubmed_id>1353628</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Cavero I, Lefevre-Borg F, Roach AG: Effects of mianserin, desipramine and maprotiline on blood pressure responses evoked by acetylcholine, histamine and 5-hydroxytryptamine in rats. Br J Pharmacol. 1981 Sep;74(1):143-8.</reference_text>
        <pubmed_id>6115693</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Kanba S, Richelson E: Histamine H1 receptors in human brain labelled with [3H]doxepin.  Brain Res. 1984 Jun 18;304(1):1-7.</reference_text>
        <pubmed_id>6146381</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desloratadine</name>
        <accession>HMDB15102</accession>
      </metabolite>
      <reference>
        <reference_text>Wu RL, Anthes JC, Kreutner W, Harris AG, West RE Jr: Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Receptor. Int Arch Allergy Immunol. 2004 Dec;135(4):313-8. Epub 2004 Nov 24.</reference_text>
        <pubmed_id>15564772</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desloratadine</name>
        <accession>HMDB15102</accession>
      </metabolite>
      <reference>
        <reference_text>Cieslewicz G, Gondorowicz K, Grzelewska-Rzymowska I, Rozniecki J: [Effect of loratadine, selective antagonist of histamine H1 receptors, on histamine-induced bronchoconstriction]. Pneumonol Alergol Pol. 1995;63(5-6):281-5.</reference_text>
        <pubmed_id>7581058</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desloratadine</name>
        <accession>HMDB15102</accession>
      </metabolite>
      <reference>
        <reference_text>Letari O, Miozzo A, Folco G, Belloni PA, Sala A, Rovati GE, Nicosia S: Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. Eur J Pharmacol. 1994 Feb 15;266(3):219-27.</reference_text>
        <pubmed_id>8174605</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desloratadine</name>
        <accession>HMDB15102</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desloratadine</name>
        <accession>HMDB15102</accession>
      </metabolite>
      <reference>
        <reference_text>Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30.</reference_text>
        <pubmed_id>18336052</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desloratadine</name>
        <accession>HMDB15102</accession>
      </metabolite>
      <reference>
        <reference_text>DuBuske L: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy.  Am J Clin Dermatol. 2007;8(5):271-83.</reference_text>
        <pubmed_id>17902729</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desloratadine</name>
        <accession>HMDB15102</accession>
      </metabolite>
      <reference>
        <reference_text>Simons FE, Prenner BM, Finn A Jr: Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003 Mar;111(3):617-22.</reference_text>
        <pubmed_id>12642846</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desloratadine</name>
        <accession>HMDB15102</accession>
      </metabolite>
      <reference>
        <reference_text>Dhanya NB, Thasleem Z, Rai R, Srinivas CR: Comparative efficacy of levocetirizine, desloratidine and fexofenadine by histamine wheal suppression test. Indian J Dermatol Venereol Leprol. 2008 Jul-Aug;74(4):361-3.</reference_text>
        <pubmed_id>18797058</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dimenhydrinate</name>
        <accession>HMDB15120</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dimenhydrinate</name>
        <accession>HMDB15120</accession>
      </metabolite>
      <reference>
        <reference_text>Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate.  Neurosci Biobehav Rev. 2002 Jan;26(1):61-7.</reference_text>
        <pubmed_id>11835984</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promethazine</name>
        <accession>HMDB15202</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promethazine</name>
        <accession>HMDB15202</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki A, Yasui-Furukori N, Mihara K, Kondo T, Furukori H, Inoue Y, Kaneko S, Otani K: Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003 Apr;25(2):192-6.</reference_text>
        <pubmed_id>12657913</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promethazine</name>
        <accession>HMDB15202</accession>
      </metabolite>
      <reference>
        <reference_text>Smith BN, Armstrong WE: Histamine enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via H1-receptor activation. Neuroscience. 1993 Apr;53(3):855-64.</reference_text>
        <pubmed_id>8098142</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promethazine</name>
        <accession>HMDB15202</accession>
      </metabolite>
      <reference>
        <reference_text>Miller RA, Tu AT: Factors in snake venoms that increase capillary permeability.  J Pharm Pharmacol. 1989 Nov;41(11):792-4.</reference_text>
        <pubmed_id>2576052</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promethazine</name>
        <accession>HMDB15202</accession>
      </metabolite>
      <reference>
        <reference_text>Claro E, Arbones L, Garcia A, Picatoste F: Phosphoinositide hydrolysis mediated by histamine H1-receptors in rat brain cortex. Eur J Pharmacol. 1986 Apr 16;123(2):187-96.</reference_text>
        <pubmed_id>3011460</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promethazine</name>
        <accession>HMDB15202</accession>
      </metabolite>
      <reference>
        <reference_text>Ikeda H, Kubo N, Nakamura A, Harada N, Minamino M, Yamashita T: Histamine-induced calcium released from cultured human mucosal microvascular endothelial cells from nasal inferior turbinate. Acta Otolaryngol. 1997 Nov;117(6):864-70.</reference_text>
        <pubmed_id>9442829</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promethazine</name>
        <accession>HMDB15202</accession>
      </metabolite>
      <reference>
        <reference_text>Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).  Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97.</reference_text>
        <pubmed_id>2866055</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mequitazine</name>
        <accession>HMDB15204</accession>
      </metabolite>
      <reference>
        <reference_text>Nakamura K, Yokoi T, Kodama T, Inoue K, Nagashima K, Shimada N, Shimizu T, Kamataki T: Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.</reference_text>
        <pubmed_id>9454781</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mequitazine</name>
        <accession>HMDB15204</accession>
      </metabolite>
      <reference>
        <reference_text>ter Laak AM, Venhorst J, Donne-Op den Kelder GM, Timmerman H: The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. J Med Chem. 1995 Aug 18;38(17):3351-60.</reference_text>
        <pubmed_id>7650688</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mequitazine</name>
        <accession>HMDB15204</accession>
      </metabolite>
      <reference>
        <reference_text>Wiseman LR, Faulds D: Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs. 1996 Feb;51(2):260-77.</reference_text>
        <pubmed_id>8808167</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mequitazine</name>
        <accession>HMDB15204</accession>
      </metabolite>
      <reference>
        <reference_text>Yakuo I, Ishii K, Seto Y, Imano K, Takeyama K, Nakamura H, Karasawa T: [Pharmacological study of ebastine, a novel histamine H1-receptor antagonist].  Nihon Yakurigaku Zasshi. 1994 Mar;103(3):121-35.</reference_text>
        <pubmed_id>7511558</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mequitazine</name>
        <accession>HMDB15204</accession>
      </metabolite>
      <reference>
        <reference_text>Wang YJ, Yu CF, Chen LC, Chen CH, Lin JK, Liang YC, Lin CH, Lin SY, Chen CF, Ho YS: Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity. J Cell Biochem. 2002;87(2):147-59.</reference_text>
        <pubmed_id>12244568</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mequitazine</name>
        <accession>HMDB15204</accession>
      </metabolite>
      <reference>
        <reference_text>Nicholson AN, Stone BM: The H1-antagonist mequitazine: studies on performance and visual function.  Eur J Clin Pharmacol. 1983;25(4):563-6.</reference_text>
        <pubmed_id>6418550</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mequitazine</name>
        <accession>HMDB15204</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Emedastine</name>
        <accession>HMDB15216</accession>
      </metabolite>
      <reference>
        <reference_text>Sharif NA, Su SX, Yanni JM: Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol. 1994 Winter;10(4):653-64.</reference_text>
        <pubmed_id>7714409</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Emedastine</name>
        <accession>HMDB15216</accession>
      </metabolite>
      <reference>
        <reference_text>Yanni JM, Stephens DJ, Parnell DW, Spellman JM: Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol. 1994 Winter;10(4):665-75.</reference_text>
        <pubmed_id>7714410</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Emedastine</name>
        <accession>HMDB15216</accession>
      </metabolite>
      <reference>
        <reference_text>Inagaki N, Sakurai T, Abe T, Musoh K, Kawasaki H, Tsunematsu M, Nagai H: Characterization of antihistamines using biphasic cutaneous reaction in BALB/c mice. Life Sci. 1998;63(11):PL 145-50.</reference_text>
        <pubmed_id>9747899</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Emedastine</name>
        <accession>HMDB15216</accession>
      </metabolite>
      <reference>
        <reference_text>Murota H, Katayama I: Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67.</reference_text>
        <pubmed_id>19558341</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Emedastine</name>
        <accession>HMDB15216</accession>
      </metabolite>
      <reference>
        <reference_text>Corrado ME, Radicioni MM, Hartwig J, Assandri A, Oldeman HG, Mion A: Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus terfenadine in the treatment of seasonal allergic rhinitis. Arzneimittelforschung. 2004;54(10):660-5.</reference_text>
        <pubmed_id>15553105</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Emedastine</name>
        <accession>HMDB15216</accession>
      </metabolite>
      <reference>
        <reference_text>Murota H, Bae S, Hamasaki Y, Maruyama R, Katayama I: Emedastine difumarate inhibits histamine-induced collagen synthesis in dermal fibroblasts. J Investig Allergol Clin Immunol. 2008;18(4):245-52.</reference_text>
        <pubmed_id>18714531</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Emedastine</name>
        <accession>HMDB15216</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levocabastine</name>
        <accession>HMDB15238</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levocabastine</name>
        <accession>HMDB15238</accession>
      </metabolite>
      <reference>
        <reference_text>Sugimoto Y, Iba Y, Ishizawa K, Suzuki G, Kamei C: Effects of levocabastine on lipid mediator release from guinea pig lung fragments. Acta Med Okayama. 1999 Dec;53(6):271-4.</reference_text>
        <pubmed_id>10631382</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levocabastine</name>
        <accession>HMDB15238</accession>
      </metabolite>
      <reference>
        <reference_text>Chalon P, Vita N, Kaghad M, Guillemot M, Bonnin J, Delpech B, Le Fur G, Ferrara P, Caput D: Molecular cloning of a levocabastine-sensitive neurotensin binding site.  FEBS Lett. 1996 May 20;386(2-3):91-4.</reference_text>
        <pubmed_id>8647296</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levocabastine</name>
        <accession>HMDB15238</accession>
      </metabolite>
      <reference>
        <reference_text>Yamada M, Yamada M, Lombet A, Forgez P, Rostene W: Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Life Sci. 1998;62(23):PL 375-80.</reference_text>
        <pubmed_id>9627096</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levocabastine</name>
        <accession>HMDB15238</accession>
      </metabolite>
      <reference>
        <reference_text>Betancur C, Canton M, Burgos A, Labeeuw B, Gully D, Rostene W, Pelaprat D: Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain. Eur J Pharmacol. 1998 Feb 5;343(1):67-77.</reference_text>
        <pubmed_id>9551716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levocabastine</name>
        <accession>HMDB15238</accession>
      </metabolite>
      <reference>
        <reference_text>Akiyoshi M, Shigeoka T, Torii S, Maki E, Enomoto S, Takahashi H, Hirano F: [Pharmacological and clinical properties of levocabastine hydrochloride (eye drop and nasal spray), a selective H1 antagonist]. Nihon Yakurigaku Zasshi. 2002 Mar;119(3):175-84.</reference_text>
        <pubmed_id>11915520</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, Funaki Y, Itoh M, Iwata R, Wong DF, Yanai K: Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol. 2004 Aug;44(8):890-900.</reference_text>
        <pubmed_id>15286093</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Tran VT, Lebovitz R, Toll L, Snyder SH: [3H]doxepin interactions with histamine H1-receptors and other sites in guinea pig and rat brain homogenates. Eur J Pharmacol. 1981 Apr 9;70(4):501-9.</reference_text>
        <pubmed_id>7238574</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Kano M, Fukudo S, Tashiro A, Utsumi A, Tamura D, Itoh M, Iwata R, Tashiro M, Mochizuki H, Funaki Y, Kato M, Hongo M, Yanai K: Decreased histamine H1 receptor binding in the brain of depressed patients.  Eur J Neurosci. 2004 Aug;20(3):803-10.</reference_text>
        <pubmed_id>15255990</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Claro E, Arbones L, Garcia A, Picatoste F: Phosphoinositide hydrolysis mediated by histamine H1-receptors in rat brain cortex. Eur J Pharmacol. 1986 Apr 16;123(2):187-96.</reference_text>
        <pubmed_id>3011460</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102.</reference_text>
        <pubmed_id>6086881</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38.</reference_text>
        <pubmed_id>19179941</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Singh H, Becker PM: Novel therapeutic usage of low-dose doxepin hydrochloride.  Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.</reference_text>
        <pubmed_id>17685877</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria.  Fundam Clin Pharmacol. 1990;4(2):147-58.</reference_text>
        <pubmed_id>2141000</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenylpyraline</name>
        <accession>HMDB15277</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenylpyraline</name>
        <accession>HMDB15277</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenylpyraline</name>
        <accession>HMDB15277</accession>
      </metabolite>
      <reference>
        <reference_text>Nakai T, Kitamura N, Hashimoto T, Kajimoto Y, Nishino N, Mita T, Tanaka C: Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol Psychiatry. 1991 Aug 15;30(4):349-56.</reference_text>
        <pubmed_id>1912125</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenylpyraline</name>
        <accession>HMDB15277</accession>
      </metabolite>
      <reference>
        <reference_text>Taniguchi K, Masuda Y, Takanaka K: Inhibitory effects of histamine H1 receptor blocking drugs on metabolic activations of neutrophils. J Pharmacobiodyn. 1991 Feb;14(2):87-93.</reference_text>
        <pubmed_id>1678430</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenylpyraline</name>
        <accession>HMDB15277</accession>
      </metabolite>
      <reference>
        <reference_text>Weis R, Schweiger K, Faist J, Rajkovic E, Kungl AJ, Fabian WM, Schunack W, Seebacher W: Antimycobacterial and H1-antihistaminic activity of 2-substituted piperidine derivatives. Bioorg Med Chem. 2008 Dec 15;16(24):10326-31. Epub 2008 Oct 22.</reference_text>
        <pubmed_id>18977145</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenylpyraline</name>
        <accession>HMDB15277</accession>
      </metabolite>
      <reference>
        <reference_text>Lapa GB, Mathews TA, Harp J, Budygin EA, Jones SR: Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties. Eur J Pharmacol. 2005 Jan 4;506(3):237-40. Epub 2004 Dec 8.</reference_text>
        <pubmed_id>15627433</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenylpyraline</name>
        <accession>HMDB15277</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Sawynok J, Esser MJ, Reid AR: Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. Pain. 1999 Aug;82(2):149-58.</reference_text>
        <pubmed_id>10467920</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Orphenadrine</name>
        <accession>HMDB15304</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Orphenadrine</name>
        <accession>HMDB15304</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Orphenadrine</name>
        <accession>HMDB15304</accession>
      </metabolite>
      <reference>
        <reference_text>Rumore MM, Schlichting DA: Analgesic effects of antihistaminics.  Life Sci. 1985 Feb 4;36(5):403-16.</reference_text>
        <pubmed_id>2578597</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclizine</name>
        <accession>HMDB15307</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclizine</name>
        <accession>HMDB15307</accession>
      </metabolite>
      <reference>
        <reference_text>Leza JC, Lizasoain I, Lorenzo P: H1- and H2-histamine receptor blockers and opiate analgesia in mice.  Methods Find Exp Clin Pharmacol. 1990 Dec;12(10):671-8.</reference_text>
        <pubmed_id>1983158</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromodiphenhydramine</name>
        <accession>HMDB15367</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromodiphenhydramine</name>
        <accession>HMDB15367</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromodiphenhydramine</name>
        <accession>HMDB15367</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aripiprazole</name>
        <accession>HMDB05042</accession>
      </metabolite>
      <reference>
        <reference_text>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17848919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorprothixene</name>
        <accession>HMDB15369</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorprothixene</name>
        <accession>HMDB15369</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimeprazine</name>
        <accession>HMDB15376</accession>
      </metabolite>
      <reference>
        <reference_text>Santos DE, Liu GJ, Takeuchi H: Blockers for excitatory effects of achatin-I, a tetrapeptide having a D-phenylalanine residue, on a snail neurone. Eur J Pharmacol. 1995 Jan 16;272(2-3):231-9.</reference_text>
        <pubmed_id>7713167</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimeprazine</name>
        <accession>HMDB15376</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Cohen LJ: Risperidone.  Pharmacotherapy. 1994 May-Jun;14(3):253-65.</reference_text>
        <pubmed_id>7524043</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone.  Psychopharmacology (Berl). 1994 Feb;114(1):9-23.</reference_text>
        <pubmed_id>7531353</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</reference_text>
        <pubmed_id>11132243</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrimeprazine</name>
        <accession>HMDB15474</accession>
      </metabolite>
      <reference>
        <reference_text>Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.</reference_text>
        <pubmed_id>2899826</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aceprometazine</name>
        <accession>HMDB15553</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aceprometazine</name>
        <accession>HMDB15553</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aceprometazine</name>
        <accession>HMDB15553</accession>
      </metabolite>
      <reference>
        <reference_text>Mercier J, Dessaigne S, Menguy A, Manez J: Electro-encephalographic study on the action of the combination meprobamate-aceprometazine on various cerebral systems. Arzneimittelforschung. 1974 Feb;24(2):163-6.</reference_text>
        <pubmed_id>4406367</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aceprometazine</name>
        <accession>HMDB15553</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenindamine</name>
        <accession>HMDB15556</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenindamine</name>
        <accession>HMDB15556</accession>
      </metabolite>
      <reference>
        <reference_text>ter Laak AM, Venhorst J, Donne-Op den Kelder GM, Timmerman H: The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. J Med Chem. 1995 Aug 18;38(17):3351-60.</reference_text>
        <pubmed_id>7650688</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenindamine</name>
        <accession>HMDB15556</accession>
      </metabolite>
      <reference>
        <reference_text>Witek TJ Jr, Canestrari DA, Miller RD, Yang JY, Riker DK: The effects of phenindamine tartrate on sleepiness and psychomotor performance.  J Allergy Clin Immunol. 1992 Dec;90(6 Pt 1):953-61.</reference_text>
        <pubmed_id>1360991</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenindamine</name>
        <accession>HMDB15556</accession>
      </metabolite>
      <reference>
        <reference_text>van Drooge MJ, Donne-op den Kelder GM, Timmerman H: The histamine H1-receptor antagonist binding site. Part I: Active conformation of cyproheptadine. J Comput Aided Mol Des. 1991 Aug;5(4):357-70.</reference_text>
        <pubmed_id>1686618</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenindamine</name>
        <accession>HMDB15556</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pheniramine</name>
        <accession>HMDB15557</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pheniramine</name>
        <accession>HMDB15557</accession>
      </metabolite>
      <reference>
        <reference_text>Leurs R, Bast A, Timmerman H: High affinity, saturable [3H]mepyramine binding sites on rat liver plasma membrane do not represent histamine H1-receptors. A warning. Biochem Pharmacol. 1989 Jul 1;38(13):2175-80.</reference_text>
        <pubmed_id>2567596</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pheniramine</name>
        <accession>HMDB15557</accession>
      </metabolite>
      <reference>
        <reference_text>Yanni JM, Stephens DJ, Parnell DW, Spellman JM: Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol. 1994 Winter;10(4):665-75.</reference_text>
        <pubmed_id>7714410</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pheniramine</name>
        <accession>HMDB15557</accession>
      </metabolite>
      <reference>
        <reference_text>Nath C, Gupta MB: Role of central histaminergic system in lorazepam withdrawal syndrome in rats.  Pharmacol Biochem Behav. 2001 Apr;68(4):777-82.</reference_text>
        <pubmed_id>11526976</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pheniramine</name>
        <accession>HMDB15557</accession>
      </metabolite>
      <reference>
        <reference_text>Karadag CH, Ulugol A, Dokmeci D, Dokmeci I: The role of histamine H1-receptors in the anticonvulsive effect of morphine against maximal electroconvulsive shock in mice. Jpn J Pharmacol. 1996 Jun;71(2):109-12.</reference_text>
        <pubmed_id>8835636</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pheniramine</name>
        <accession>HMDB15557</accession>
      </metabolite>
      <reference>
        <reference_text>Nosal R, Drabikova K, Jancinova V, Moravcova J, Lojek A, Ciz M, Macickova T, Pecivova J: H1-antihistamines and oxidative burst of professional phagocytes.  Neuro Endocrinol Lett. 2009;30 Suppl 1:133-6.</reference_text>
        <pubmed_id>20027159</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pheniramine</name>
        <accession>HMDB15557</accession>
      </metabolite>
      <reference>
        <reference_text>Gepdiremen A, Buyukokuroglu ME, Hacimuftuoglu A, Suleyman H: Contribution of the histaminergic receptor subtypes to histamine-induced cerebellar granular neurotoxicity. Pol J Pharmacol. 2003 May-Jun;55(3):383-8.</reference_text>
        <pubmed_id>14506317</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pheniramine</name>
        <accession>HMDB15557</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlophedianol</name>
        <accession>HMDB15585</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlophedianol</name>
        <accession>HMDB15585</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlophedianol</name>
        <accession>HMDB15585</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlophedianol</name>
        <accession>HMDB15585</accession>
      </metabolite>
      <reference>
        <reference_text>Maurer H, Pfleger K: Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. J Chromatogr. 1988 Aug 19;430(1):31-41.</reference_text>
        <pubmed_id>2905706</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunarizine</name>
        <accession>HMDB15589</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunarizine</name>
        <accession>HMDB15589</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunarizine</name>
        <accession>HMDB15589</accession>
      </metabolite>
      <reference>
        <reference_text>Taylor JE, Defeudis FV: Interactions of verapamil, D 600, flunarizine and nifedipine with cerebral histamine-receptors. Neurochem Int. 1986;9(3):379-81.</reference_text>
        <pubmed_id>20493137</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bepotastine</name>
        <accession>HMDB15600</accession>
      </metabolite>
      <reference>
        <reference_text>Andoh T, Kuraishi Y: Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice. Eur J Pharmacol. 2006 Oct 10;547(1-3):59-64. Epub 2006 Jul 25.</reference_text>
        <pubmed_id>16914135</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bepotastine</name>
        <accession>HMDB15600</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mianserin</name>
        <accession>HMDB15620</accession>
      </metabolite>
      <reference>
        <reference_text>Csaba G, Kovacs P, Pallinger E: Prolonged effect of the tricyclic antidepressant, mianserin on the serotonin and histamine content of young rats' white blood cells and mast cells. A case of late-imprinting. Pharmacol Res. 2003 Nov;48(5):457-60.</reference_text>
        <pubmed_id>12967590</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mianserin</name>
        <accession>HMDB15620</accession>
      </metabolite>
      <reference>
        <reference_text>Grinshpoon A, Valevski A, Moskowitz M, Weizman A: Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients. Eur Psychiatry. 2000 Sep;15(6):388-90.</reference_text>
        <pubmed_id>11004734</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mianserin</name>
        <accession>HMDB15620</accession>
      </metabolite>
      <reference>
        <reference_text>Nowak JZ, Arrang JM, Schwartz JC, Garbarg M: Interaction between mianserin, an antidepressant drug, and central H1- and H2-histamine-receptors: in vitro and in vivo studies and radioreceptor assay. Neuropharmacology. 1983 Mar;22(3):259-66.</reference_text>
        <pubmed_id>6302549</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mepyramine</name>
        <accession>HMDB15639</accession>
      </metabolite>
      <reference>
        <reference_text>Moriyama K, Liu J, Jang Y, Chae YJ, Wang Y, Mitchell J, Grond S, Han X, Xing Y, Xie GX, Pierce Palmer P: Receptor mediation and nociceptin inhibition of bradykinin-induced plasma extravasation in the knee joint of the rat. Inflamm Res. 2009 Dec;58(12):873-80. Epub 2009 Jun 21.</reference_text>
        <pubmed_id>19544046</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mepyramine</name>
        <accession>HMDB15639</accession>
      </metabolite>
      <reference>
        <reference_text>Chhabria MT, Patel VT, Rajan KS, Brahmkshatriya PS: Design, synthesis and histamine H1-receptor antagonistic activity of some novel 4-amino-2-(substituted)-5-(substituted) aryl-6-[(substituted aryl) amino] pyrimidines. Arzneimittelforschung. 2009;59(5):243-7.</reference_text>
        <pubmed_id>19537525</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mepyramine</name>
        <accession>HMDB15639</accession>
      </metabolite>
      <reference>
        <reference_text>Mojtahedin A, Tamaddonfard E, Zanboori A: Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54.</reference_text>
        <pubmed_id>19552055</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mepyramine</name>
        <accession>HMDB15639</accession>
      </metabolite>
      <reference>
        <reference_text>Parsons ME, Ganellin CR: Histamine and its receptors.  Br J Pharmacol. 2006 Jan;147 Suppl 1:S127-35.</reference_text>
        <pubmed_id>16402096</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mepyramine</name>
        <accession>HMDB15639</accession>
      </metabolite>
      <reference>
        <reference_text>Snowman AM, Snyder SH: Cetirizine: actions on neurotransmitter receptors.  J Allergy Clin Immunol. 1990 Dec;86(6 Pt 2):1025-8.</reference_text>
        <pubmed_id>1979798</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Betahistine</name>
        <accession>HMDB15644</accession>
      </metabolite>
      <reference>
        <reference_text>Barak N: Betahistine: what's new on the agenda?  Expert Opin Investig Drugs. 2008 May;17(5):795-804.</reference_text>
        <pubmed_id>18447604</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Betahistine</name>
        <accession>HMDB15644</accession>
      </metabolite>
      <reference>
        <reference_text>Lacour M, Sterkers O: Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs. 2001;15(11):853-70.</reference_text>
        <pubmed_id>11700150</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Antazoline</name>
        <accession>HMDB15689</accession>
      </metabolite>
      <reference>
        <reference_text>Swiader MJ, Luszczki JJ, Wielosz M, Czuczwar SJ: Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. Pharmacol Rep. 2005 Jul-Aug;57(4):531-5.</reference_text>
        <pubmed_id>16129921</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloropyramine</name>
        <accession>HMDB15690</accession>
      </metabolite>
      <reference>
        <reference_text>Budihna M, Drevensek G, Burjak M, Kocijancic S: Effects of chloropyramine and famotidine on postischaemic and posthypoxic myocardial damage in isolated rat hearts. Pflugers Arch. 1996;431(6 Suppl 2):R217-8.</reference_text>
        <pubmed_id>8739342</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dimethindene</name>
        <accession>HMDB15691</accession>
      </metabolite>
      <reference>
        <reference_text>Moree WJ, Li BF, Zamani-Kord S, Yu J, Coon T, Huang C, Marinkovic D, Tucci FC, Malany S, Bradbury MJ, Hernandez LM, Wen J, Wang H, Hoare SR, Petroski RE, Jalali K, Yang C, Sacaan A, Madan A, Crowe PD, Beaton G: Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5874-8. Epub 2010 Aug 3.</reference_text>
        <pubmed_id>20800486</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dimethindene</name>
        <accession>HMDB15691</accession>
      </metabolite>
      <reference>
        <reference_text>Pfaff O, Hildebrandt C, Waelbroeck M, Hou X, Moser U, Mutschler E, Lambrecht G: The (S)-(+)-enantiomer of dimethindene: a novel M2-selective muscarinic receptor antagonist. Eur J Pharmacol. 1995 Nov 24;286(3):229-40.</reference_text>
        <pubmed_id>8608784</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isothipendyl</name>
        <accession>HMDB15692</accession>
      </metabolite>
      <reference>
        <reference_text>Moreau A, Dompmartin A, Dubreuil A, Leroy D: Phototoxic and photoprotective effects of topical isothipendyl.  Photodermatol Photoimmunol Photomed. 1995 Apr;11(2):50-4.</reference_text>
        <pubmed_id>8546983</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
